Allakos (STU:37Z) Total Liabilities : €67.46 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Allakos Total Liabilities?

Allakos's Total Liabilities for the quarter that ended in Mar. 2024 was €67.46 Mil.

Allakos's quarterly Total Liabilities increased from Sep. 2023 (€58.52 Mil) to Dec. 2023 (€68.59 Mil) but then declined from Dec. 2023 (€68.59 Mil) to Mar. 2024 (€67.46 Mil).

Allakos's annual Total Liabilities declined from Dec. 2021 (€79.07 Mil) to Dec. 2022 (€71.73 Mil) and declined from Dec. 2022 (€71.73 Mil) to Dec. 2023 (€68.59 Mil).

Allakos Total Liabilities Historical Data

The historical data trend for Allakos's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allakos Total Liabilities Chart

Allakos Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

19.06

53.61

79.07

71.73

68.59

Allakos Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															65.34	59.27	58.52	68.59	67.46

Allakos Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Allakos's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	33.542	+	(35.043	+	-7.105427357601E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	68.59

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	223.39	-	154.805
	=	68.59

Allakos's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	33.047	+	(34.415	+	0.00099999999999767
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	67.46

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	163.127	-	95.664
	=	67.46

Allakos Total Liabilities Related Terms

Thank you for viewing the detailed overview of Allakos's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Allakos (STU:37Z) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (STU:37Z) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ALLK:USA

Address

825 Industrial Road, Suite 500, San Carlos, CA, USA, 94070

Website

https://www.allakos.com

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.

Allakos (STU:37Z) Headlines

No Headlines